Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Concern With Potential Rise in Super Potent Cannabis Concentrates

By University of Queensland | July 24, 2017

Concern over the rise in use of super potent cannabis. Source: University of Queensland

University of Queensland researchers are concerned the recent legalisation of medicinal cannabis in Australia may give rise to super-potent cannabis concentrates with associated harmful effects.

UQ Centre for Youth Substance Abuse Research’s Dr Gary Chan, who led the butane hash oil study, said a significant proportion of cannabis users used the concentrate.

“Butane hash oil is a cannabis concentrate that is over 10 times more potent than herbal cannabis,” Dr Chan said.

“Although users were more likely to report medical use, the use of butane hash oil was associated with high levels of depression, anxiety disorder and other illicit substance use.

“These results were consistent globally.”

The research was based on data from the Global Drug Survey, the world’s largest drug survey that collects data about drug users.

The tetrahydrocannabinol (THC) content of butane hash oil can be as high as 80 per cent. In comparison, the THC content in herbal cannabis is approximately 9-15 per cent, depending on the method of cultivation.

Butane hash oil is produced by solvent extraction (maceration, infusion or percolation) of marijuana or hashish.

After filtering and evaporating the solvent, a sticky resinous dark liquid with a strong herbal odour remains.

Dr Chan said there had been a rise of butane hash oil use in the United States, and considered it to be an unexpected by-product of cannabis legalisation.

“The production and promotion of hyper-potent cannabis concentrates with 70 to 80 per cent THC now account for 20 per cent of the markets in Washington and Colorado, and use of these hyper-potent products seem to be gaining popularity in Canada,” he said.

“Given that Australia has recently legalised medical cannabis use, surveillance needs to take note of any rise in the use of concentrates because it can be produced with relatively simple equipment that is easily accessible.

“However, at this stage there is no evidence for medical use of butane hash oil for any health condition.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE